Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Eaton Vance fund managers see major upside for healthcare stocks: Barron's

Published 07/16/2017, 05:13 PM
Updated 07/16/2017, 05:20 PM
© Reuters.  Eaton Vance fund managers see major upside for healthcare stocks: Barron's

© Reuters. Eaton Vance fund managers see major upside for healthcare stocks: Barron's

(Reuters) - The portfolio managers of the $1.2 billion Eaton Vance Worldwide Health Sciences fund are expecting big gains from a trio of healthcare stocks.

Jason Kritzer and Samantha Pandolfi, co-managers of the fund, highlighted Vertex Pharmaceuticals (O:VRTX), Zoetis (N:ZTS) and Shire (L:SHP) for future outperformance in an article in Barron's.

Kritzer said he expects to see Vertex increase its revenue by at least 20 percent in 2017 and 30 percent in 2018, with per-share profit potentially doubling this year and again next year. He sees the stock price rising to "between $152 and $155."

Vertex closed at $130.99 on Friday.

Pandolfi says she sees 15 percent upside for drugmaker Zoetis and 40 percent upside for Dublin-based drugmaker Shire.She said Shire's stock price has been held back by investor concerns the company is losing ground to other manufacturers of hemophilia drugs, which Shire relies on for a large portion of its annual revenue.

"If the hemophilia fears persist, it could take two to three years to deliver those returns," she said. "If the fears abate, it will happen sooner."

The pair said that the pharmaceutical and biotechnology industries have been proactive in the face of uncertainty surrounding the possible repeal of the Affordable Care Act, noting also that "The leaked draft executive order on drug pricing reads favorably for industries. With repeal and replace [of the Affordable Care Act], depending on how things shake out, hospitals are the big losers long term, due to cuts in Medicaid."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.